Obecabtagene autoleucel
2025-0580
Phase 2 small_molecule active
Quick answer
Obecabtagene autoleucel for Acute Lymphocytic Leukemia (ALL) is a Phase 2 program (small_molecule) at Autolus Therapeutics plc with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Autolus Therapeutics plc
- Indication
- Acute Lymphocytic Leukemia (ALL)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active